In contrast, the recently reported novel orally active TSHR-targeting ligand A35 effectively inhibits human thyroid cancer proliferation and metastasis both in vitro and in vivo as a standalone treatment, showing minimal toxicity and strong potential as a lead compound for DTC therapy (94). This evidence concerns the gene TSHR and thyroid cancer.